Fulcrum Therapeutics, Inc.
FULC
Rank in Stocks
#15080
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed... Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Share Price
$3.72
Last synced: 2026-11-09
Market Cap
$283.83M
Change (1 day)
0.54%
Change (1 year)
-54.36%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Fulcrum Therapeutics, Inc. (FULC)
Category
Healthcare
EPS for Fulcrum Therapeutics, Inc. (FULC)
EPS as of June 2026 TTM: $-1.21
According to Fulcrum Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.21. At the end of 2025 the company had an EPS of $-1.18, a decrease compared to its 2024 EPS of $-0.16.
EPS history for Fulcrum Therapeutics, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.21 | 2.54% |
| 2025 | $-1.18 | 637.50% |
| 2024 | $-0.16 | -89.94% |
| 2023 | $-1.59 | -32.34% |
| 2022 | $-2.35 | 5.86% |
| 2021 | $-2.22 | -17.78% |
| 2020 | $-2.70 | -22.64% |
| 2019 | $-3.49 | 81.77% |
| 2018 | $-1.92 | 41.18% |
| 2017 | $-1.36 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,394.21% |
US
|
|
| $-7.07 | 484.30% |
US
|
|
| $-5.29 | 337.19% |
AU
|
|
| $12.88 | -1,164.47% |
BE
|
|
| $21.56 | -1,881.82% |
NL
|
Questions about Fulcrum Therapeutics, Inc.'s earnings per share (EPS)
What is Fulcrum Therapeutics, Inc.'s earnings per share (EPS)?
Fulcrum Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.21, as of Jun 2026.
What was Fulcrum Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Fulcrum Therapeutics, Inc.'s earnings per share (EPS) was $-1.18, compared with $-0.16 in 2024.
How has Fulcrum Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Fulcrum Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-0.16) and lowest in 2020 ($-2.70).
How does Fulcrum Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Fulcrum Therapeutics, Inc.'s earnings per share (EPS) ($-1.21) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.